0000000000548107
AUTHOR
Murray B. Urowitz
A framework for remission in SLE
ObjectivesTreat-to-target recommendations have identified ‘remission’ as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE.MethodsAn international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%.ResultsThe task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:1. Definitions of remission wi…
P124 The impact of the new American college of cardiology/american heart association (ACC/AHA) definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus
Background The 2017 ACC/AHA guidelines define hypertension as ≥130/80 mmHg instead of ≥140/90 mmHg. Studies in systemic autoimmune diseases, where blood pressure (BP) is fluctuating over time, were not considered. Our aim was to assess the impact of the new definition on the prevalence and incidence of atherosclerotic vascular events (AVEs) in systemic lupus erythematosus (SLE). Patients-Methods SLE patients with at least two years of follow-up and no previous AVEs were divided in three groups (≥140/90 mmHg, 130–139/80–89 mmHg and Results 1532 patients satisfied the inclusion criteria (88.1% females, mean age at baseline 36.2±14.3 years, mean disease duration 6.1±6.3 years). The prevalence …